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ibrillation in the Cardiac Catheterization
aboratory Among Patients Receiving
rimary Percutaneous Coronary Intervention
ncidence, Predictors, and Outcomes
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OBJECTIVES We sought to evaluate the incidence, predictors, and outcomes of ventricular tachycardia
and/or ventricular fibrillation (VT/VF) in the cardiac catheterization laboratory among
patients undergoing primary percutaneous coronary intervention (PCI).
BACKGROUND Although VT/VF has been known to occur during primary PCI, the current data do not
identify patients at risk for these arrhythmias or the outcomes of such patients.
METHODS We evaluated 3,065 patients enrolled in the Primary Angioplasty in Myocardial Infarction
(PAMI) trials, who underwent primary PCI to evaluate the associations of VT/VF and the
influence of these arrhythmias on in-hospital and one-year outcomes.
RESULTS In patients undergoing primary PCI, VT/VF occurred in 133 (4.3%). Multivariate analysis
identified the following as independent correlates of VT/VF: smoking (odds ratio [OR] 1.95,
95% confidence interval [CI] 1.26 to 3.02), lack of preprocedural beta-blockers (OR 2.34,
95% CI 1.35 to 4.07), time from symptom onset to emergency room of 180 min (OR 2.63,
95% CI 1.42 to 4.89), initial Thrombolysis In Myocardial Infarction (TIMI) flow grade 0
(OR 2.06, 95% CI 1.23 to 3.47), and right coronary artery-related infarct (OR 1.93, 95% CI
1.25 to 2.99). Although patients with VT/VF had a higher incidence of bradyarrhythmias,
hypotension, cardiopulmonary resuscitation, and endotracheal intubation in the catheteriza-
tion laboratory, their in-hospital and one-year adverse outcomes were similar to those of the
cohort without these arrhythmias.
CONCLUSIONS Our findings suggest that the incidence of VT/VF during primary PCI is low, indicating that
these arrhythmias do not influence PCI success or in-hospital or one-year outcomes. Our data
further help identify patients at risk of VT/VF during primary PCI and suggest that
pretreatment with beta-blockers should be strongly considered to reduce these
arrhythmias. (J Am Coll Cardiol 2004;43:1765–72) © 2004 by the American College of
Cardiology Foundationr
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tany studies have investigated the clinical and angio-
raphic correlates and the prognostic significance of sus-
ained ventricular tachycardia and/or ventricular fibrillation
VT/VF) after thrombolytic therapy in patients with ST-
egment elevation myocardial infarction (STEMI) (1–6).
See page 1788
ome of these investigations have suggested that these
entricular arrhythmias are associated with coronary reper-
usion, although others have related them to suboptimal
From the *University of Michigan, Ann Arbor, Michigan; †William Beaumont
ospital, Royal Oak, Michigan; ‡Lenox Hill Hospital, New York, New York; and
Mid Carolina Cardiology, Charlotte, North Carolina.
Manuscript received June 17, 2003; revised manuscript received August 27, 2003,dccepted September 8, 2003.eperfusion (1–6). The occurrence of VT/VF after throm-
olysis has been shown to be associated with an increased
isk of in-hospital and one-year adverse events (6).
However, much less is known about the incidence, risk
actors, and prognosis of sustained VT/VF occurring in the
ardiac catheterization laboratory in patients with STEMI
ndergoing primary percutaneous coronary intervention
PCI). It is unclear how the rapid reperfusion achieved with
rimary PCI (with an associated rapid change in the
etabolic cellular milieu, resulting in regional electrophysi-
logic instability), on the one hand, and the more complete
eperfusion, on the other (7–10), influence the propensity
nd outcomes of these arrhythmias after primary PCI. The
urpose of the current investigation was to examine the
ncidence, predictors, and outcomes of VT/VF occurring in
he cardiac catheterization laboratory among patients un-
ergoing primary PCI.
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atient population. We pooled the data on 3,065 patients
nrolled in the four Primary Angioplasty in Myocardial
nfarction (PAMI) studies (including two trials with their
oncomitant registries) that collected prospective data on
omplications occurring in the cardiac catheterization lab-
ratory (7,11–15). The rationale, methodology, and results
f the individual PAMI studies have been previously pub-
ished (7,11–15). Patients were included in these investiga-
ions if they were 18 years old with STEMI presenting
ithin 12 h of their symptom onset. Acute STEMI was
efined as ST-segment elevation of at least 1 mm in two or
ore contiguous leads or presumed new left bundle branch
lock on the presenting 12-lead electrocardiogram (ECG)
n the presence of chest pain and/or elevation of cardiac
nzymes. Patients were excluded from these trials if they
ad contraindications to reperfusion, had received throm-
olytic therapy for index STEMI, or had renal failure,
ardiogenic shock, or a life expectancy 1 year; those with
hild-bearing potential; or those with known contraindica-
ions to aspirin, heparin, or ticlopidine in later PAMI trials
11,14,15). Furthermore, patients randomized to the
hrombolytic arm in PAMI-1 were also excluded from this
nalysis (7). Informed consent was obtained from all pa-
ients by the study investigators at the respective
nstitutions.
ata collection and angiographic analyses. A research
oordinator at each site collected data prospectively on
respecified data elements on a case-report form in all trials.
hese data included baseline demographics, medical history
as reported by the patients, their families, or their referring
hysicians, or determined from their previous medical
ecords), medications, procedures, complications, and clin-
cal events. Follow-up was obtained at one year by a
elephone interview or follow-up visit to the physician.
ompleted case-report forms were sent to the coordinating
ite at Beaumont Hospital, Royal Oak, Michigan, where the
ata were entered into an Access data base. The cineangio-
rams obtained at the time of the index intervention were
nalyzed at the core laboratory site, where coronary anat-
Abbreviations and Acronyms
CI  confidence interval
ECG  electrocardiogram/electrocardiographic
OR  odds ratio
PAMI  Primary Angioplasty in Myocardial Infarction
trial
PCI  percutaneous coronary intervention
RCA  right coronary artery
STEMI  ST-segment elevation myocardial infarction
TIMI  Thrombolysis In Myocardial Infarction
VF  ventricular fibrillation
VT  ventricular tachycardiamy, Thrombolysis In Myocardial Infarction (TIMI) flow Crades, percent diameter stenosis, left ventricular ejection
raction, and angiographic outcomes of the intervention
ere assessed.
efinitions, group comparisons, and study end points.
e categorized the study patients into two groups: those
ith and those without sustained VT/VF occurring in the
ardiac catheterization laboratory during primary PCI. Ven-
ricular fibrillation was defined as irregular undulations of
arying contour and amplitude on the ECG, with absent
istinct QRS and T waves and hemodynamic compromise
equiring direct-current defibrillation (Fig. 1A). Sustained
T was defined as a regular wide-complex tachycardia of
entricular origin lasting 30 s and/or accompanied by
emodynamic compromise requiring electrical cardioversion
r anti-arrhythmic therapy (Fig. 1B). Re-infarction was
efined as recurrent symptoms or development of new ECG
hanges accompanied by new elevation of creatine kinase,
B enzyme levels. Ischemia-driven target vessel revascu-
arization was defined as PCI or coronary artery bypass graft
urgery of the index infarct-related artery prompted by
ymptoms or objective evidence of ischemia. Sustained
ypotension was defined as systolic blood pressure80 mm
g that was unresponsive to intravenous fluids, requiring
asopressors for 1 h or an intra-aortic balloon pump. For
his study, we compared the baseline clinical characteristics,
atient demographic features, coronary angiographic find-
ngs, and in-hospital adverse events of the two comparison
roups. The principal outcomes of interest included differ-
nces in the in-hospital and one-year mortality rates and the
n-hospital and one-year incidence of major adverse cardio-
ascular events (defined as death, or re-infarction, or isch-
mic target vessel revascularization) between these two
roups.
tatistical analysis. Summary statistics are presented as
requencies and percentages or as median values. Compar-
sons between the two study groups were made using the
wo-tailed Wilcoxon rank-sum test for continuous variables
nd the chi-square or Fisher exact test (when the expected
requency count in a cell was5) for categorical variables, as
ppropriate. In all cases, denominators reflect cases re-
orted. Stepdown multivariate logistic regression was con-
tructed to identify clinical predictors of sustained VT/VF,
sing variables showing a marginal association with it on
nivariate testing (p  0.10). Only variables with a signif-
cant (p  0.05) association with sustained VT/VF were
ncluded in the final regression models. Adjusted odds ratios
ORs) and accompanying 95% confidence intervals (CIs)
ere computed to determine the effect of each variable on
he risk of VT/VF in the final model. Diagnostic routines
the Hosmer-Lemeshow test for lack of fit and the likeli-
ood ratio test) were used for the final model selection. The
statistic was calculated to evaluate model discrimination.
he Cochran-Mantel-Haenszel test was used for the anal-
sis of trend. The software SAS version 8.0 (SAS Institute,
ary, North Carolina) was utilized for all analyses.
1767JACC Vol. 43, No. 10, 2004 Mehta et al.
May 19, 2004:1765–72 Ventricular Arrhythmias Treated With Primary PCIFigure 1. Electrocardiographic tracings of ventricular fibrillation (A) and ventricular tachycardia (B) during primary percutaneous coronary intervention.
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linical and angiographic characteristics of patients with
nd without VT/VF (Tables 1 and 2). Of the 3,065
atients with STEMI undergoing primary PCI in the study,
33 (4.3%) had VT/VF during the procedure. The majority
f patients with VT/VF required cardioversion/defibrillation
79%), whereas anti-arrhythmic drugs were used to restore
inus rhythm in the remaining patients. Compared with the
ohort without VT/VF, those with these arrhythmias were
ore likely to be current smokers, with a trend toward being
f younger age. Other patient demographics and medical
istory were similar in the two groups. The time from
ymptom onset to emergency room presentation was shorter
n the group with VT/VF, with no difference in the
oor-to-balloon time. Systolic blood pressure on arrival was
ower in patients with VT/VF. Aspirin, heparin, and beta-
lockers were given less frequently before arriving at the
ardiac catheterization laboratory in patients with VT/VF.
s a result, the first activated clotting time in the catheter-
zation laboratory was significantly lower in these patients.
Important differences also existed in the angiographic
haracteristics between the two groups. Patients with
T/VF were more likely to have initial TIMI flow grade 0,
Table 1. Baseline Characteristics of Study Pati
No
Mean age (yrs)
Age 70 yrs
Females
Onset of symptom to ER (min) 16
ER to balloon time (min) 14
Medical history
Previous angina
Previous myocardial infarction
Previous congestive heart failure
Diabetes
Hypertension
Previous stroke
Hyperlipidemia
Peripheral vascular disease
Current smoker
Previous PCI
Previous CABG
COPD
Presentation
Pulse (beats/min)
Pulse 100 beats/min
Systolic blood pressure (mm Hg)
Systolic blood pressure 100 mm Hg
Killip class I
Medications before PCI
Aspirin
Heparin
Ticlopidine
Beta-blockers
*Derived using the Fisher exact test. Data are presented as t
CABG  coronary artery bypass grafting; COPD  chro
percutaneous coronary intervention; SD  standard deviatioigher initial percent stenosis of the infarct-related artery, Vnd the right coronary artery (RCA) as their infarct artery.
he postprocedural final percent stenosis and non–flow-
imiting infarct artery dissection were higher in patients
ith VT/VF, with no difference between other postproce-
ural angiographic features, such as TIMI flow rates or the
resence of thrombus.
omplications in the catheterization laboratory, in the
ospital, and at one-year follow-up in patients with and
ithout VT/VF (Tables 2 and 3). Patients with VT/VF
ad a significantly higher incidence of bradyarrhythmias,
ypotension, cardiopulmonary resuscitation, and the need
or endotracheal intubation in the catheterization labora-
ory. Despite this, neither the mortality in the catheteriza-
ion laboratory nor the in-hospital or one-year adverse
utcomes differed between the two groups. The median
ength of stay was a day longer in the VT/VF group.
linical factors related to VT/VF (Table 4). Stepdown
ogistic regression analysis identified current smoking,
horter time from symptom onset to emergency room
resentation, lack of beta-blocker therapy in the emergency
oom, RCA-related STEMI, and lower TIMI flow grades
n admission as independent correlates of VT/VF. By
mputing the presence or absence of these risk variables for
F Group
2,932)
VT/VF Group
(n  133) p Value
12 58  12 0.057
(25%) 25 (19%) 0.13
(27%) 33 (25%) 0.64
75 (111) 116  89 (89) 0.014
61 (113) 145  119 (120) 0.27
(15%) 21 (16%) 0.76
(14%) 17 (13%) 0.56
(1.9%) 4 (3%) 0.32*
(16%) 15 (11%) 0.12
(46%) 55 (41%) 0.33
(5.3%) 6 (4.5%) 0.72
(35%) 52 (39%) 0.42
(5.7%) 6 (4.5%) 0.57
(41%) 72 (54%) 0.0024
(9.3%) 13 (9.8%) 0.84
(4.3%) 3 (2.3%) 0.29*
(2.7%) 1 (0.8%) 1.00*
20 86  21 0.95
19 26  23 0.38
25 107  22 0.0015
26 46  40 0.0011
11.2 15  11.7 0.84
(83%) 102 (77%) 0.036
(71%) 82 (62%) 0.044
(36%) 29 (22%) 0.26
(29%) 19 (14%) 0.0003
an  SD (median) value or number (%) of subjects.
structive pulmonary disease; ER  emergency room; PCI 
 ventricular fibrillation; VT  ventricular tachycardia.ents
VT/V
(n 
61 
718
780
4  1
3  1
451
425
55
479
1,349
154
1,018
167
1,207
272
125
78
87 
512 
114 
675 
322 
2,425
2,074
1,066
854
he me
nic obT/VF in a patient (yes  1; no  0) into the equation
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May 19, 2004:1765–72 Ventricular Arrhythmias Treated With Primary PCIhown in the Appendix and solving this equation, an
stimate of the absolute risk of VT/VF in an individual
atient during primary PCI can be obtained. The frequency
f VT/VF increased as the time from symptom onset to
mergency room arrival decreased (Fig. 2). Also, the fre-
uency of VT/VF increased as the number of risk predictors
ncreased: from none in patients with no risk factors to
2.6% in those with all five risk variables (Fig. 3).
ISCUSSION
indings of the present study. Our study suggests that
T/VF occurs infrequently in the cardiac catheterization
aboratory in patients undergoing primary PCI and identi-
es clinical and angiographic factors associated with this
dverse event. Importantly, it shows that although the
ccurrence of VT/VF during primary angioplasty is associ-
Table 2. Angiographic Data and Catheterizatio
Initial angiographic data
Infarct-related artery
LMCA
LAD
LCx
RCA
Bypass graft
Multivessel disease
TIMI flow grade
0
1
2
3
Percent stenosis
LVEF (%)
Medications, IABP, and stent use during procedure
Glycoprotein IIb/IIIa inhibitors
Thrombolytics
Stents
IABP
Initial activated clotting time (s)
Postprocedural angiographic data
TIMI flow grade
0
1
2
3
Percent stenosis
Thrombus
Final dissection
Catheterization laboratory complications
Bradyarrhythmias
Cardiopulmonary resuscitation
Endotracheal intubation
Hypotension
Death
*Derived using the Fischer exact test. Data are presented as
IABP  intra-aortic balloon pump; LAD  left anterior
 left main coronary artery; LVEF  left ventricular ejectio
In Myocardial Infarction; VF  ventricular fibrillation; VTted with a greater length of stay, it does not have an impact pn the procedural success or risk of adverse in-hospital and
ong-term outcomes.
Thus, our study findings are in contrast to those of large
rials evaluating VT/VF in patients with STEMI receiving
hrombolytic therapy, which have reported a higher inci-
ence of up to 20% and a greater risk of adverse short- and
ong-term outcomes with this arrhythmia (1–6). Previous
tudies have shown that the size of myocardial infarction not
nly correlates with an increased incidence of VT/VF, but is
lso an important predictor of mortality in patients with
TEMI (5,6,16–18). Compared with thrombolysis, pri-
ary PCI is associated with greater myocardial salvage, a
maller infarct size, and a better ejection fraction (7–10). In
atients treated with thrombolytic therapy, failed reperfu-
ion is more common in the cohort with VT/VF than in
hose without these arrhythmias (6). Primary PCI is asso-
iated with not only more complete reperfusion (and fewer
aboratory Complications of Study Patients
o VT/VF Group
(n  2,932)
VT/VF Group
(n  133) p Value
18 (0.6%) 1 (0.8%)
1,111 (37.8%) 38 (28.6%) 0.018
431 (14.7%) 15 (11.3%) 0.23
1,199 (40.8%) 77 (57.9%) 0.0002
39 (1.3%) 0
1,414 (48.2%) 53 (40%) 0.068
1,754 (59.8%) 105 (78.9%) 0.0008
332 (11.3%) 7 (5.3%)
419 (14.3%) 12 (9%)
324 (11%) 8 (6%)
97.4  7 (100) 98.7  4 (100) 0.0007
49  12 50  12 0.51
62 (2.1%) 5 (3.7%) 0.40
125 (4.3%) 10 (7.5%) 0.28
894 (31%) 35 (26.3%) 0.30
38 (1.3%) 5 (3.7%) 0.16
234  159 167  182  0.0001
39 (1.3%) 0
21 (0.7%) 0
137 (4.6%) 6 (4.5%)
2,417 (82.4%) 123 (92.5%) 0.22
16  18 (10) 18  15 (20) 0.024
247 (8.4%) 18 (13.5%) 0.24
341 (11.6%) 29 (21.8%) 0.018
281 (9.6%) 46 (34.6%)  0.0001
13 (0.4%) 8 (6%)  0.0001
20 (0.7%) 6 (4.5%)  0.0018
141 (4.8%) 21 (15.8%)  0.0001
3 (0.1%) 1 (0.7%) 0.19*
mber (%) of subjects or mean  SD (median) value.
ding coronary artery; LCx  left circumflex artery; LMCA
tion; RCA  right coronary artery; TIMI  Thrombolysis
tricular tachycardia.n L
N
the nu
descen
n fracatients with TIMI flow grade 0), but also rapid reperfusion
(
o
o
l
l
C
o
s
i
i
h
e
e
fl
t
c
o
t
p
b
l
l
g
e
a
p
l
d
r
p
b
w
t
r
d
a
d
p
t
b
w
F
f
C
F
v
t
T
I
M
I
O
*
e
r
T
W
P
C
N
R
T
I
M
1770 Mehta et al. JACC Vol. 43, No. 10, 2004
Ventricular Arrhythmias Treated With Primary PCI May 19, 2004:1765–727–10). Thus, it is not surprising that unlike previous reports
f VT/VF occurring after thrombolysis (1–6), the incidence
f ventricular arrhythmias occurring with primary PCI is
ow and does not increase the risk of in-hospital and
ong-term mortality.
linical and angiographic factors associated with the risk
f VT/VF in patients undergoing primary PCI. Our
tudy identified several clinical and angiographic variables as
ndependent predictors of VT/VF in the cardiac catheter-
zation laboratory during primary PCI. These included a
istory of current smoking, time from symptom onset to
mergency room arrival, lack of beta-blocker therapy in the
mergency room, RCA-related infarct, and initial TIMI
ow grade 0 of the infarct-related artery.
Nicotine stimulates catecholamine release and increases
he heart rate and blood pressure (19). An increased level of
arbon monoxide in smokers further reduces myocardial
able 3. In-Hospital Complications and Long-Term Outcomes
No VT/VF
Group
(n  2,932)
VT/VF
Group
(n  133)
p
Value
n-hospital events
Bradyarrhythmias 71 (2.4%) 7 (5.3%) 0.080
Pulmonary edema 80 (2.7%) 7 (5.3%) 0.23
Sustained hypotension 106 (3.6%) 9 (6.7%) 0.23
Cardiopulmonary resuscitation 19 (0.6%) 0 1.00*
Need for dialysis 13 (0.4%) 0 1.00*
CABG 245 (8.3%) 7 (5.2%) 0.23
Gastrointestinal bleeding 63 (2.1%) 4 (3%) 0.34*
edian length of stay (days) 5 6 0.019
n-hospital outcomes
Re-infarction 33 (1.1%) 1 (0.8%) 1.00*
Ischemic TVR 87 (2.9%) 7 (5.3%) 0.12
Death 84 (2.9%) 4 (3.0%) 0.79
MACE 182 (6.2%) 11 (8.3%) 0.34
Disabling stroke 6 (0.2%) 0 1.00*
ne-year outcomes
Re-infarction 97 (3.3%) 3 (2.2%) 1.00*
Ischemic TVR 312 (10.6%) 18 (13.5%) 0.09
Death 163 (5.5%) 6 (4.5%) 0.72
MACE 528 (18%) 24 (18%) 0.75
Disabling stroke 12 (0.4%) 0 1.00*
Derived using the Fisher exact test. Data are presented as the number (%) of subjects.
CABG  coronary artery bypass graft; MACE  major adverse cardiovascular
vents (re-infarction, or ischemia driven TVR or death); TVR  target vessel
evascularization; other abbreviations as in Table 1.
able 4. Adjusted Odds Ratios of Clinical Variables Associated
ith the Risk of Ventricular Tachycardia or Fibrillation During
rimary Percutaneous Coronary Intervention
Outcome
Odds
Ratio
95%
Confidence
Interval p Value
urrent smoker 1.95 1.26–3.02 0.0027
o beta-blocker in the ER 2.34 1.35–4.07 0.0026
CA as infarct artery 1.93 1.25–2.99 0.0033
ime from symptom onset
to ER 180 min
2.63 1.42–4.89 0.0022
nitial TIMI flow grade 0 2.06 1.23–3.47 0.0062
odel c statistic  0.72; Hosmer-Lemeshow chi-square  6.03; df 8; p  0.64.
ER  emergency room. Other abbreviations as in Tables 1 and 2.xygen delivery (20). In addition, smoking has been shown
o injure endothelial cells (21) and reduce prostacyclin
roduction (22). These effects induce coronary vasospasm of
oth epicardial and myocardial resistance vessels, particu-
arly in diseased coronary arteries. Smokers are also more
ikely to be younger—a population that is likely to have
reater catecholamine surge with stress, as compared with
lderly patients. Thus, both increased catecholamine levels
nd a greater propensity for vasospasm may make smokers
articularly susceptible to VT/VF after primary PCI, which
eads to rapid electrophysiologic instability of the myocar-
ium.
The speed of reperfusion has been shown to increase the
ate of reperfusion arrhythmias. In animal studies, brief
eriods (5 to 15 min) of coronary artery occlusion followed
y reperfusion are often associated, at the time of reflow,
ith dramatic increase in ventricular arrhythmias (23,24). If
he duration of ischemia is extended to 1 to 3 h, followed by
eperfusion, ventricular arrhythmias may still be present
uring the phase of ischemia, but reperfusion is not associ-
ted with as dramatic an increase in VT/VF (25). Clinical
ata support these preliminary animal observations. A
ooled analysis of intracoronary thrombolysis trials suggests
hat VT/VF was more likely to occur when the interval
etween the onset of infarction and thrombolytic therapy
as short (25). Similarly, in patients receiving intravenous
igure 2. Time from symptom onset to emergency room (ER) arrival and
requency of ventricular tachycardia/ventricular fibrillation (VT/VF). The
ochran-Mantel-Haenszel statistic  9.2, df 1, p  0.0024 for trend.
igure 3. Increasing number of risk factors for ventricular tachycardia/
entricular fibrillation (VT/VF) (as shown in Table 4) and the incidence of
hese arrhythmias. The Cochran-Mantel-Haenszel statistic  50.7, df 1, p0.0001 for trend.
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May 19, 2004:1765–72 Ventricular Arrhythmias Treated With Primary PCIhrombolysis, VT/VF was more likely to occur when the
ime to treatment was shorter (6,26). The inverse relation-
hip of the time from symptom onset to emergency room
nd the risk of VT/VF in our study is thus consistent with
hese previous observations.
The use of beta-blockers in patients with STEMI in the
re-thrombolysis era has been shown to be associated with
reduction in early mortality, cardiac rupture, and ventric-
lar arrhythmias (27,28). This beneficial effect of beta-
lockers in reducing the incidence of VT/VF was also
hown in patients receiving thrombolytic therapy (6). Our
ata are consistent with these earlier observations and
xtend the paradigm of the benefits of beta-blockers to
atients receiving primary PCI. Thus, previous studies and
ur investigation suggest that beta-blockers are not only
seful in preventing ischemia-mediated VT/VF (in non-
eperfused patients), but also in reducing the incidence of
hese arrhythmias. These findings argue in favor of routine
se of early beta-blocker therapy for all patients with
TEMI, including those receiving primary PCI, to reduce
he incidence of VT/VF, as well as to improve outcomes.
Similar to the finding in our investigation, the risk of
T/VF has been shown to increase in patients with STEMI
elated to the RCA, who are receiving thrombolytic therapy
5,6,18), even in those undergoing rescue angioplasty (29).
everal potential mechanisms may be implicated in this
ncreased risk of VT/VF during reperfusion of an infarct
elated to the RCA. Sudden reperfusion of the RCA
ncreases vagal tone through the Bezold-Jarisch reflex,
hich, in turn, results in a marked compensatory increase in
ympathetic tone (29). Further, RCA-related infarctions are
ore common among younger patients and smokers (30),
ndividuals who are more likely to have markedly height-
ned sympathetic tone, particularly after stress such as
TEMI.
Finally, animal studies have demonstrated that the sever-
ty of ischemic injury governs the extent of reperfusion
njury (23,24). The greater the degree of myocardial hypo-
erfusion, the greater is the rate of formation of free radicals
ith reperfusion, and hence the greater chance of reperfu-
ion arrhythmias (31). An increased heart rate worsens the
everity of ischemic injury, augmenting the incidence of
eperfusion arrhythmias (32). Conversely, agents that re-
uce the heart rate (beta-blockers) decrease reperfusion
rrhythmias (33). Our investigation concurs with these
nimal experiments in that VT/VF was more common in
atients undergoing primary PCI who had more severe
schemia at the onset (those with TIMI flow grade 0),
ompared with those with a lesser severity of ischemia
TIMI flow grade 1). Also, patients with TIMI flow
rade 0 are more likely to have true reperfusion arrhythmias,
s opposed to those with partial flow (TIMI flow grade1).
onclusions. Our study suggests that in patients undergo-
ng primary PCI, VT/VF occurs infrequently in the cardiac
atheterization laboratory and does not influence PCI suc-
ess or in-hospital or one-year outcomes when treatedromptly. Our data further help identify clinical and angio-
raphic variables associated with an increased risk of these
rrhythmias during primary PCI and suggest that prophy-
actic treatment with beta-blockers may be the best strategy
o prevent ventricular arrhythmias in patients undergoing
rimary PCI.
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PPENDIX
alculation of predicted risk using patient data and
ogistic regression coefficients. To calculate the odds of
isk of VT/VF during the procedure for an individual
ndergoing primary PCI: exp ([5.7521]  [0.6690 
urrent smoker]  [0.8504  beta-blocker therapy in
mergency room]  [0.6576  RCA as infarct-related
rtery]  [0.9676  time from symptom onset to emer-
ency room arrival 180 min]  [0.7243  initial TIMI
ow grade 0]). In the equation, the risk variables in a patient
ndergoing primary PCI are entered as: present  1;
bsent  0. The predicted risk (probability) of VT/VF
uring primary angioplasty is calculated as: odds/(1 
dds).
